Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

It’s Too Early to Tell Whether ‘This Time, It’s Different’ Applies to Ethereum

By Thomas Niel, InvestorPlace Contributor

With the risk that the overheated crypto market pulls back further, take your time before entering a position in Ethereum.

5 Mid-Cap Stocks With a Ton of Cash

By Thomas Niel, InvestorPlace Contributor

Cash is king for these five reasonably priced mid-cap stocks with cash on hand totaling 20% (or more) of their market capitalization.

Tread Carefully, but Stellar Lumens May Have More Room to Run

By Thomas Niel, InvestorPlace Contributor

Yet, as retail investor mania for both speculative stocks and speculative cryptos remains, prices could continue to rise. Those who are willing to risk big losses could find opportunity here with Stellar Lumen. However, tread carefully. More speculative coins like this one could see more dramatic declines if the "crypto bubble" pops in the coming year.

7 Biotech Stocks Focused on Chronic Covid Treatment

By Thomas Niel, InvestorPlace Contributor

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

VG Acquisition Stock Will Continue to Underwhelm SPAC Investors

By Thomas Niel, InvestorPlace Contributor

With more than 50% possible downside, and questionable upside, there's little reason to dabble in VGAC stock at today's prices.

Load More